Raf De Wilde is Senior Executive Advisor at Valid Insight. Valid Insight is an award-winning pharmaceutical global market access consultancy. With a team that includes some of the world’s leading market access and pricing experts, clients across the globe turn to us for innovative pricing, market access and value communication strategies through the full product development cycle. Proud winners of the Queen’s Award for Enterprise: International Trade in 2019.
Raf is a global expert in life science market access, having over 39 years’ experience in the pharmaceutical industry and over 29 years in global market access for life science products. Raf became head of International Marketing Services within Janssen Pharmaceutica (a Johnson & Johnson (J&J) company) in 1991, introducing Health Economics at J&J that year. Raf was Chairman of the EPhMRA Primary Research and Methods Committee (1993-1995). He became VP of EPhMRA in 1994 and 1997 and President in 1995 and 1998.
In 1997, he joined Peter Lauper’s team that pioneered the ‘biosimilars’ concept and the first patient access schemes. Raf led a specialist oncology, real-world evidence and virology group between 2002 and 2004, where he created a center of excellence for oncology pricing and specialized in biologics while leading the HEOR function at CEN TOCOR . Raf was VP of Market Access at J&J leading teams working on oncology, cardiovascular and biotech products.
Raf joined United Biosource Corporation (UBC) as Associate VP in early 2011 and stayed with Evidera until 2015, prior to joining Valid Insight in 2016. In his consulting career, he has led nearly 200 global market access projects, including value strategies, price finding research, patient access schemes, negotiation tactics, tendering and contracting, WHO classification and naming strategies. He has moderated over 150 training workshops in Asia, Asia-Pacific, Europe, North America and the Middle East, and led the life sciences pricing training of the European Pricing Platform from 2011 to 2014.
Raf continues to teach the sessions on PRO s and evidence-based medicine for the Master of Science in Pharmaceutical Medicine course of the University of Duisburg-Essen in Germany.